278 related articles for article (PubMed ID: 22891351)
21. Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.
Hwang ES; Kim DW; Hwang JH; Jung HS; Suh JM; Park YJ; Chung HK; Song JH; Park KC; Park SH; Yun HJ; Kim JM; Shong M
Mol Endocrinol; 2004 Nov; 18(11):2672-84. PubMed ID: 15297606
[TBL] [Abstract][Full Text] [Related]
22. Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.
Pilli T; Prasad KV; Jayarama S; Pacini F; Prabhakar BS
Thyroid; 2009 Dec; 19(12):1333-42. PubMed ID: 20001716
[TBL] [Abstract][Full Text] [Related]
23. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
24. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.
Charles RP; Iezza G; Amendola E; Dankort D; McMahon M
Cancer Res; 2011 Jun; 71(11):3863-71. PubMed ID: 21512141
[TBL] [Abstract][Full Text] [Related]
25. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
26. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
28. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
[TBL] [Abstract][Full Text] [Related]
29. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
30. Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas.
Kim WG; Choi HJ; Kim WB; Kim EY; Yim JH; Kim TY; Gong G; Kim SY; Chung N; Shong YK
J Endocrinol Invest; 2012 Apr; 35(4):413-8. PubMed ID: 21897114
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH
Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
Henderson YC; Ahn SH; Kang Y; Clayman GL
Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
[TBL] [Abstract][Full Text] [Related]
33. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
[TBL] [Abstract][Full Text] [Related]
34. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.
Ryder M; Gild M; Hohl TM; Pamer E; Knauf J; Ghossein R; Joyce JA; Fagin JA
PLoS One; 2013; 8(1):e54302. PubMed ID: 23372702
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
36. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
[TBL] [Abstract][Full Text] [Related]
37. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.
Cross-Knorr S; Lu S; Perez K; Guevara S; Brilliant K; Pisano C; Quesenberry PJ; Resnick MB; Chatterjee D
BMC Cancer; 2013 Oct; 13():463. PubMed ID: 24098947
[TBL] [Abstract][Full Text] [Related]
38. BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.
Rusinek D; Swierniak M; Chmielik E; Kowal M; Kowalska M; Cyplinska R; Czarniecka A; Piglowski W; Korfanty J; Chekan M; Krajewska J; Szpak-Ulczok S; Jarzab M; Widlak W; Jarzab B
PLoS One; 2015; 10(12):e0143688. PubMed ID: 26625260
[TBL] [Abstract][Full Text] [Related]
39. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
[TBL] [Abstract][Full Text] [Related]
40. Clinical prognosis in BRAF-mutated PTC.
Puxeddu E; Moretti S
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):736-47. PubMed ID: 17891237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
